Over 3 Million Eye Drops Recalled Amid Sterility Concerns
via HealthDayMONDAY, April 6, 2026 — More than 3 million bottles of over-the-counter eye drops are being recalled after officials raised concerns about the product's safety.
The U.S. Food and Drug Administration (FDA) said the recall affects 3,111,072 bottles made by K.C. Pharmaceuticals of Pomona, California.
The agency said the recall was issued due to a "lack of assurance of sterility," NBC News reported.
The eye drops were sold under several names, including:
They were available at major retailers such as CVS, Walgreens and Rite Aid, the FDA said.
There have been no reports of injuries linked to the drops so far.
The FDA classified this as a Class II recall, which means the products could cause temporary or medically reversible health problems.
It’s not yet clear what caused the issue, either.
The recall includes several types of 0.5-ounce (15 mL) bottles, NBC News reported. Among them:
Sterile Eye Drops Soothing Tears (polyethylene glycol 400 0.4% and propylene glycol 0.3%), 0.5 OZ 0.5 fl oz (15 mL) bottles
A complete list of affected drops and where they were sold is available on the FDA website.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-07 01:53
Read more
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
- Women With DM Receive Less Recommended Preventive Care Than Those Without DM
- AI Scribe Use Modestly Reduces Clinical Documentation Time
- Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-Positive NSCLC
- Early-Onset Oral Cavity Squamous Cell Carcinoma Increasingly Presenting as Tongue Tumors
- Phase III Study Results with Bayer’s FXIa Inhibitor Asundexian Demonstrating Substantial Reduction in Ischemic Stroke with No Increase in ISTH Major Bleeding Versus Placebo Published in New England Journal of Medicine
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions